Clinical Scorecard: Combined Strategies for Targeting Nuclear Receptors in the Treatment of Tuberculosis and Diabetes Co-morbidity
At a Glance
Category
Detail
Condition
Key Mechanisms
Targeting nuclear receptors (Vdr, Rev-erbα, Lxr) to manage metabolic and infectious responses, as demonstrated by reduced TB burden and improved metabolic parameters in the study.
Target Population
Care Setting
Key Highlights
Combination therapy significantly alleviates metabolic and infectious symptoms in a mouse model, with specific reductions in blood glucose and TB disease burden.
Guideline-Based Recommendations
Diagnosis
Management
Consider nuclear receptor modulation as a therapeutic strategy for TB-T2DM comorbidity, including specific ligands for Vdr, Rev-erbα, and Lxr.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients with concurrent tuberculosis and type 2 diabetes mellitus.
Combination therapy using specific ligands for Vdr, Rev-erbα, and Lxr shows promise.
Clinical Best Practices
Implement integrated care strategies for managing TB and diabetes, such as regular monitoring of blood glucose and TB markers.
